Executive Director
Quantitative Clinical Pharmacology, Daiichi-Sankyo, Inc
Dr. Tushar Garimella has more than 15 years of experience in the Pharmaceutical Industry focused on the Clinical Pharmacology and Pharmacometrics aspects of drug development.
Dr. Garimella’s education includes a BPharm from the Bombay College of Pharmacy and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore. He started his industry career in Abbott Laboratories followed by Bristol-Myers Squibb. Currently, Dr. Garimella is an Executive Director and oncology portfolio lead in the Quantitative Clinical Pharmacology department at Daiichi Sankyo Inc.
Dr. Garimella has wide ranging experiences in both exploratory development and late-stage development across multiple therapeutic areas, including neuroscience and pain, oncology and immunology, virology and cardiovascular health. He has worked on multiple registrational projects, supporting submissions for FDA, EMA, PMDA, China CDE and Rest of the World.
Dr. Garimella has published more than 30 manuscripts and 50 abstracts in peer reviewed journals and international conferences throughout his career.